Empower your strategies with our Net Present Value Model: AstraZeneca Plc’s AZD-0120 report and make more profitable business decisions.
Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development.
Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.

AstraZeneca Plc’s AZD-0120 Drug Details:
GC0-12 is under development for the treatment of advanced relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, refractory generalized myasthenia gravis, B-cell non-Hodgkin’s lymphoma, primary mediastinal b-cell lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, mantle cell lymphoma and systemic lupus erythematosus. The therapy constitutes of genetically manipulated T cells which express dual chimeric antigen receptor targeting tumor cells expressing B-cell maturation antigen (BCMA) and CD19 chimeric antigen receptors. It is developed based on FasTCAR platform. It is administered through intravenous route.
Report Coverage
GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.
Scope of Report
- Drug Name
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
- Patent law
- Known and Projected regulatory approval processes
- Cash flows
- Potential applicable patients
- Drug margins
- Company expenses
- Pricing estimates
Reasons to buy
- Obtain a better understanding of the quantitative value of Net Present Value Model: AstraZeneca Plc’s AZD-0120.
- Access another data source to use in the valuation of Net Present Value Model: AstraZeneca Plc’s AZD-0120.
- Create or support internal NPV models to improve accuracy.
- Understand a drug’s expected profit, considering revenue and cost forecasts leveraging public and proprietary data sets.







